CAPR
Wall Street’s giving Capricor a nod
Capricor Therapeutics is having one of those biotech moments where the Street can’t quite agree, but the vibe is still mostly upbeat. Ten brokerages now call it a “Moderate Buy”, with nine buys and one sell, and the average 12-month target sits at $46.09.
That’s not exactly a golden ticket, but it does tell you analysts still see room for the story to work. And in biotech, “room to work” is basically Wall Street code for: we like the science, now please don’t blow it up.
The plot twist: the stock is juggling more than one headline
The article also flags some insider selling, including the CFO and a director trimming shares in March. That doesn’t automatically mean anything shady — executives sell for all kinds of reasons — but when you pair it with a fresh earnings miss, it adds a little spice to the narrative.
Capricor also just reported a quarterly loss of $0.62 per share, missing expectations. So the stock is getting a classic biotech cocktail: analyst optimism on one side, cash-burn-and-losses reality on the other.
Why you should care
If you own the stock, analyst targets can help support sentiment and keep buyers interested. But the real question is whether Capricor’s lead program can keep moving toward meaningful clinical or regulatory wins — because that’s the stuff that turns “moderate buy” into something a lot more exciting.
Big picture: Wall Street still likes the story, but Capricor has to keep earning that enthusiasm the hard way.